Kliniken Essen-Mitte


Essen, Germany

Publications in cooperation with FAU scientists

Go to first page Go to previous page 1 of 3 Go to next page Go to last page
Wunderle, M., Pretscher, J., Brucker, S.Y., Volz, B., Hartmann, A., Fiessler, C.,... Rauh, C. (2019). Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. Breast Cancer Research and Treatment, 174(2), 453-461. https://dx.doi.org/10.1007/s10549-018-05115-6
Buckley, M.A., Woods, N.T., Tyrer, J.P., Mendoza-Fandino, G., Lawrenson, K., Hazelett, D.J.,... Freedman, M.L. (2019). Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus. Cancer Research, 79(3). https://dx.doi.org/10.1158/0008-5472.CAN-17-3864
Lux, M.P., Nabieva, N., Hildebrandt, T., Rebscher, H., Kummel, S., Blohmer, J.-U., & Schrauder, M.G. (2018). Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany. BREAST , 37, 89-98. https://dx.doi.org/10.1016/j.breast.2017.11.002
Cao, J., Wiesweg, M., Fuchs, M., Stein, A., Karthaus, M., Lettmaier, S.,... Kasper, S. (2018). Efficacy and safety of Trifluridin/Tipiracil (FTD/TPI) (Lonsurf (R)) in patients with metastatic colorectal cancer (CRC) in clinical-routine use. (pp. 289-289).
Untch, M., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C.,... Loibl, S. (2018). Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). In ANNALS OF ONCOLOGY (pp. 60-60). Munich, DE: OXFORD: OXFORD UNIV PRESS.
Loibl, S., Weber, K., Huober, J., Krappmann, K., Marme, F., Schem, C.,... Denkert, C. (2018). Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. Clinical Cancer Research, 24(14), 3358-3365. https://dx.doi.org/10.1158/1078-0432.CCR-17-2947
Kelemen, L.E., Earp, M., Fridley, B.L., Chenevix-Trench, G., Fasching, P.A., Beckmann, M.,... Berchuck, A. (2018). rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 19(9). https://dx.doi.org/10.3390/ijms19092473
Denkert, C., Von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B.I., Weber, K.E.,... Loibl, S. (2018). Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncology, 19(1), 40-50. https://dx.doi.org/10.1016/S1470-2045(17)30904-X
Glubb, D.M., Johnatty, S.E., Quinn, M.C.J., O'Mara, T.A., Tyrer, J.P., Gao, B.,... Chenevix-Trench, G. (2017). Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. Oncotarget, 8(39), 64670-64684. https://dx.doi.org/10.18632/oncotarget.18501
Harbeck, N., Saupe, S., Jaeger, E., Schmidt, M., Kreienberg, R., Mueller, L.,... Al-Batran, S.-E. (2017). A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. Breast Cancer Research and Treatment, 161(1), 63-72. https://dx.doi.org/10.1007/s10549-016-4033-3
Kuemmel, S., Jackisch, C., Mueller, V., Schneeweiss, A., Klawitter, S., & Lux, M.P. (2017). Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit?.
Lux, M.P., Schrauder, M.G., Hildebrandt, T., Nabieva, N., Kuemmel, S., & Blohmer, J.-U. (2017). Comparative budget impact assessment of the different breast cancer genomic tests in Germany. (pp. S102-S103).
Kar, S.P., Adler, E., Tyrer, J., Hazelett, D., Anton-Culver, H., Bandera, E.V.,... Lawrenson, K. (2017). Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 116(4), 524-535. https://dx.doi.org/10.1038/bjc.2016.426
Kuemmel, S., & Hack, C. (2017). Event Announcement 3rd Symposium of the AGO Commission Integrative Medicine: "Integrative Medicine: Holistic Care with Natural Healing Procedures". Geburtshilfe und Frauenheilkunde, 77(8), 853-853.
Hahnen, E., Lederer, B., Hauke, J., Loibl, S., Kroeber, S., Schneeweiss, A.,... Schmutzler, R.K. (2017). Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncology, 3(10), 1378-1385. https://dx.doi.org/10.1001/jamaoncol.2017.1007
Klein, E., Beckmann, M., Bader, W., Brucker, C., Dobos, G., Fischer, D.,... Hack, C. (2017). Gynecologic oncologists' attitudes and practices relating to integrative medicine: results of a nationwide AGO survey. Archives of gynecology and obstetrics, 296(2), 295-301. https://dx.doi.org/10.1007/s00404-017-4420-y
Hack, C., Fasching, P., Fehm, T., De Waal, J., Rezai, M., Baier, B.,... Paepke, D. (2017). Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. Integrative Cancer Therapies, 16(2), 165-175. https://dx.doi.org/10.1177/1534735416668575
Loibl, S., De La Pena, L., Nekljudova, V., Zardavas, D., Michiels, S., Denkert, C.,... Loi, S. (2017). Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). European journal of cancer, 85, 133-145. https://dx.doi.org/10.1016/j.ejca.2017.08.020
Sucheston-Campbell, L.E., Cannioto, R., Clay, A.I., Etter, J.L., Eng, K.H., Liu, S.,... Moysich, K.B. (2017). No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiology Biomarkers & Prevention, 26(3), 420-424. https://dx.doi.org/10.1158/1055-9965.EPI-16-0631
Kuemmel, S., Paepke, S., Huober, J., Schem, C., Untch, M., Blohmer, J.U.,... Loibl, S. (2017). Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). European journal of cancer, 84, 1-8. https://dx.doi.org/10.1016/j.ejca.2017.06.037

Last updated on 2016-10-05 at 08:26